Thymosin Alpha-1 vs MOTS-c: Switching Between Them

What Each Peptide Actually Does

Thymosin alpha-1 and MOTS-c share a label ("peptides") but operate in completely different biological compartments. Understanding that distinction is the first step before considering a switch.

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide originally isolated from thymic tissue. It activates toll-like receptors (TLR-9 and TLR-2) on dendritic cells, promoting maturation of T-helper 1 (Th1) lymphocytes and stimulating natural killer cell activity [1]. Romani et al. demonstrated that thymosin alpha-1 restored immune function in immunocompromised states, with particular relevance in chronic hepatitis B and C infections, where it increased sustained virological response rates when combined with interferon-alpha [1]. The peptide has been approved as Zadaxin in over 35 countries for hepatitis B treatment, though it lacks FDA approval in the United States. In oncology, it has been used as an adjunctive agent to reduce immunosuppression from chemotherapy. A meta-analysis of 12 randomized controlled trials involving thymalfasin in hepatitis B found that adding it to interferon therapy increased HBeAg seroconversion by approximately 15 percentage points compared to interferon alone [3].

MOTS-c operates in an entirely different domain. This 16-amino-acid peptide is encoded by the mitochondrial genome (specifically within the 12S rRNA gene) and was first characterized by Lee et al. in Cell Metabolism (2015), who described it as "a novel mitochondrial-derived peptide that regulates metabolic homeostasis" [2]. In diet-induced obese mice, MOTS-c administration improved insulin sensitivity, reduced fat mass, and enhanced glucose uptake in skeletal muscle. The proposed mechanism involves activation of the AMPK pathway and upregulation of genes in the folate-methionine cycle. A 2021 study by Reynolds et al. found that endogenous MOTS-c levels increased in skeletal muscle during exercise in human subjects, and that the peptide translocated to the nucleus to regulate adaptive gene expression under metabolic stress [4].

The bottom line: thymosin alpha-1 is an immune peptide. MOTS-c is a metabolic peptide. They do not compete for the same receptors, pathways, or clinical indications.

Comparing the Evidence Base

The evidence gap between these two peptides is significant, and that gap should inform any decision to use or switch between them.

Thymosin alpha-1 has the stronger clinical portfolio. It has been studied in over 80 clinical trials across hepatitis B, hepatitis C, HIV, non-small cell lung cancer, hepatocellular carcinoma, and sepsis. In a randomized controlled trial of 101 patients with chronic hepatitis B, thymalfasin 1.6 mg twice weekly for 6 months achieved a 40.6% complete response rate (HBV DNA clearance plus ALT normalization) at 18-month follow-up compared to 9.4% in placebo [5]. In sepsis, a 2018 multicenter trial (N=361) reported that thymosin alpha-1 reduced 28-day mortality from 35.0% to 26.0% in patients with severe sepsis, with the most pronounced benefit in those with low monocyte HLA-DR expression [6].

MOTS-c evidence remains almost entirely preclinical. Lee et al. reported that mice treated with MOTS-c (5 mg/kg/day IP for 7 days) on a high-fat diet showed significantly lower weight gain and improved insulin sensitivity compared to controls [2]. The peptide prevented diet-induced insulin resistance when administered preventively. But no completed Phase I, II, or III human trial of exogenous MOTS-c has been published in a peer-reviewed journal as of mid-2026. Small open-label observations exist, but without control groups or standardized endpoints. Dr. Pinchas Cohen, whose laboratory at the University of Southern California first identified MOTS-c, has noted that "translating mitochondrial-derived peptide biology from rodent models to human therapeutics requires careful dose-finding studies that have not yet been completed" [7].

This asymmetry matters. Switching from a peptide with human trial data to one without means accepting a meaningfully different risk-benefit profile.

When Switching Makes Clinical Sense

A switch from thymosin alpha-1 to MOTS-c (or vice versa) is not a lateral move between interchangeable agents. It is a change in therapeutic target.

Consider switching from thymosin alpha-1 to MOTS-c when the primary clinical goal has shifted from immune modulation to metabolic optimization. A patient who initially used thymosin alpha-1 for post-viral immune recovery might later prioritize body composition, insulin sensitivity, or mitochondrial function. In that scenario, continuing an immune-stimulating peptide offers diminishing returns while a metabolic peptide addresses the new goal directly.

Consider switching from MOTS-c to thymosin alpha-1 when immune support becomes the priority. Patients preparing for chemotherapy, managing chronic viral infections, or recovering from prolonged immunosuppressive states might benefit from thymosin alpha-1's documented effects on T-cell maturation and dendritic cell function [1].

Three questions should guide the decision:

1. Has the original clinical goal been achieved or changed? If thymosin alpha-1 was used for a defined immune indication and that indication has resolved, continuing it without a new immune target is not evidence-based.

2. Does the patient have measurable metabolic dysfunction? Fasting insulin, HOMA-IR, HbA1c, or body composition data can help determine whether MOTS-c's proposed mechanism is relevant. Without baseline metabolic markers, the switch lacks a measurable endpoint.

3. Is the patient willing to accept the evidence trade-off? Moving from a peptide with Phase III data to one with preclinical-only evidence is a meaningful step. The patient should understand this clearly.

How to Switch: Practical Protocol Considerations

No peer-reviewed protocol for switching between thymosin alpha-1 and MOTS-c exists. The following approach is based on the known pharmacokinetics and pharmacodynamics of each peptide.

Stopping thymosin alpha-1. The peptide has a half-life of approximately 2 hours after subcutaneous injection [8]. It does not accumulate significantly, and immunological effects begin tapering within days of discontinuation. No rebound immunosuppression has been documented in clinical trials. A reasonable approach is to complete the current dosing cycle (most protocols use 1.6 mg SC twice weekly for 4 to 26 weeks), then discontinue. No formal washout period is pharmacologically necessary before starting MOTS-c, because the two peptides act on non-overlapping receptor systems.

Starting MOTS-c. Without standardized human dosing, protocols in the peptide therapy space have typically used 5 to 10 mg subcutaneous injection, administered two to three times per week. Some practitioners begin at 5 mg three times weekly and titrate based on metabolic markers at 4 to 6 weeks. Baseline labs before starting should include fasting glucose, fasting insulin, HbA1c, a comprehensive metabolic panel, and body composition assessment.

Switching in the opposite direction (MOTS-c to thymosin alpha-1). Stop MOTS-c at any point. Begin thymosin alpha-1 at 1.6 mg SC twice weekly. Baseline labs should include a CBC with differential, absolute lymphocyte subsets (CD4, CD8, NK cell counts), and immunoglobulin levels if immune deficiency is suspected.

Monitoring after the switch. Recheck relevant labs at 6 and 12 weeks. For thymosin alpha-1, track lymphocyte subsets and clinical immune markers. For MOTS-c, track fasting insulin, HOMA-IR, and body composition.

Safety Profiles Compared

Thymosin alpha-1 has a well-characterized safety profile across thousands of patients in clinical trials. A comprehensive review in Annals of the New York Academy of Sciences noted that adverse events were minimal, with injection-site discomfort being the most common complaint [1]. No dose-limiting toxicities were identified in hepatitis B trials at the standard 1.6 mg twice-weekly dose. Autoimmune flares are a theoretical concern with any immune-stimulating agent, but clinical data have not shown increased rates of autoimmune events in thymosin alpha-1 trials. Patients with active autoimmune disease should use thymosin alpha-1 with caution and under close monitoring.

MOTS-c safety data in humans is limited to small, uncontrolled observations. Preclinical data in mice did not reveal organ toxicity at the doses studied [2]. As a naturally occurring endogenous peptide (humans produce MOTS-c in mitochondria), the theoretical safety profile may be favorable, but "theoretical" is not "established." Without Phase I dose-escalation data, the maximum tolerated dose in humans remains undefined. Hypoglycemia is a theoretical concern given the insulin-sensitizing mechanism, particularly in patients concurrently using metformin, GLP-1 agonists, or exogenous insulin.

Neither peptide has known drug-drug interactions with common medications, though thymosin alpha-1 has been studied in combination with interferon-alpha and interleukin-2 without significant additive toxicity [1].

Regulatory and Access Considerations

Thymosin alpha-1 (brand name Zadaxin, manufactured by SciClone Pharmaceuticals) is approved in over 35 countries, including multiple European and Asian nations, for chronic hepatitis B. The U.S. FDA granted it orphan drug designation for hepatitis B and malignant melanoma but has not approved it for any indication [9]. In the U.S., thymosin alpha-1 is available through compounding pharmacies registered under Section 503B, though its regulatory status has shifted; the FDA's updated bulk drug substance list under the Drug Quality and Security Act affects availability periodically.

MOTS-c has no regulatory approval in any country. It is available as a research peptide from compounding pharmacies and peptide suppliers. Quality assurance varies significantly across sources. Third-party certificate of analysis (COA) testing for identity, purity (>98%), and endotoxin levels is the minimum standard patients and practitioners should require before use.

Patients switching between these peptides need to verify sourcing for each independently. A pharmacy that reliably supplies one may not carry the other.

Who Should Not Switch

Not every patient is a candidate for switching, even if the clinical goal has changed.

Patients actively undergoing treatment for hepatitis B or C should not discontinue thymosin alpha-1 in favor of MOTS-c. The immune indication takes priority, and MOTS-c has no antiviral data. Patients with type 1 diabetes or insulin-dependent type 2 diabetes should approach MOTS-c cautiously given the lack of human dosing data in these populations and the risk of hypoglycemia when stacking insulin-sensitizing compounds.

Patients with active autoimmune conditions (lupus, rheumatoid arthritis, multiple sclerosis) should avoid thymosin alpha-1 given its Th1-polarizing effects, which could exacerbate certain autoimmune flares. Dr. Enrico Garaci, who published extensively on thymosin alpha-1 immunology, observed that "the Th1/Th2 balancing properties of thymalfasin are context-dependent, and in patients with pre-existing Th1-driven autoimmunity, careful clinical judgment is required" [3].

Pregnant or breastfeeding individuals should not use either peptide. Neither has reproductive toxicology data in humans.

The Cost Factor

Thymosin alpha-1 from U.S. 503B compounding pharmacies typically runs $150 to $400 per month at the standard twice-weekly 1.6 mg protocol, depending on the pharmacy and whether the patient uses a subscription model. MOTS-c is generally less expensive per milligram from peptide suppliers ($80 to $250 per month at typical protocols), though the total cost depends on dosing frequency and the markup from the prescribing clinic.

Neither peptide is covered by insurance in the United States for any indication. Patients should factor ongoing lab monitoring costs into the total expense, particularly when switching, since the baseline lab panels differ between immune and metabolic indications.